Up 27.4% at constant USD rates to EUR 79.5 million
In EUR millions | 2006 | 2007 | Change | Change at constant USD rates |
First quarter | 18.3 | 21.2 | +15.6% | +22.9% |
Second quarter | 16.3 | 20.6 | +26.4% | +32.6% |
Third quarter | 15.1 | 18.3 | +21.7% | +27.2% |
Fourth quarter | 16.5 | 19.4 | +17.6% | +27.2% |
12 months | 66.2 | 79.5* | +20.1% | +27.4% |
* Including the integration of HP Botanicals on April 1, 2007.
Naturex posted full-year revenues of EUR 79.5 million in 2007, an increase of 20.1% (27.4% at constant USD rates) on 2006. Organic** growth stood at 5.8% at current USD rate and at 12.1% at constant USD rate.
Including over 12 months HP Botanicals (acquired on April 1, 2007), Chart Corporation (acquired on December 20, 2007) and Berkem's Active Ingredients division , 2007 pro-forma revenues totaled EUR 88.9 million. Revenues break down as follows: neutraceuticals 56.5%, flavoring and food processing 32.2%, pharmaceuticals 5.5% and cosmetics 2.0%. The United States represented 59.1% of revenues, Europe 24.2%, France 9.7% and Asia/Oceania 3.7%.
Outlook for 2008
Naturex will continue to broaden its sales network in 2008 with the setting up of a subsidiary in China and the opening of two sales offices, one in Germany which will also cover the Benelux countries in the first half of the year and the other in Japan in the second half of the year.
The Group intends to generate double-digit organic growth at constant USD rates in 2008.
** by integrating Hammer Pharma and HP Botanicals over 12 months in 2006 and 2007.
Your contact
NATUREX Jacques Dikansky – President and CEO Phone. : +33 4 90 23 96 89 j.dikansky@naturex.com |
ACTUS Coralie Vogt – Financial PR Phone : +33 1 53 67 35 79 cvogt@actus.fr |
NATUREX has been listed since October 1996
Eurolist by Euronext Paris, segment B - ISIN: FR0000054694
Reuters NATU.LN - Bloomberg NTRX:FP